Bayer's Kogenate approved for paediatric prophylaxis in haemophilia
This article was originally published in Scrip
Executive Summary
Bayer HealthCare's Kogenate FS (sucrose formulated recombinant Factor VIII) has received US FDA approval for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children aged 0-16 years with severe haemophilia A with no pre-existing joint damage.